Merck, hedging its bets against Bristol-Myers Squibb and AstraZeneca, strikes up Keytruda-CTLA4 combo trial
admin 9th June 2017 Uncategorised 0It remains to be seen whether chemo or CTLA4 will emerge as the preferred partner for PD-1/PD-L1 medications in first-line lung cancer. So Merck is trialing both.
More: Merck, hedging its bets against Bristol-Myers Squibb and AstraZeneca, strikes up Keytruda-CTLA4 combo trial
Source: fierce